上市委員會擬取消鮮馳達控股(01175.HK)上巿地位
格隆匯1月30日丨鮮馳達控股(01175.HK)公吿,於2023年1月20日,聯交所發函通知公司由2023年2月9日上午9時正起,公司股份上巿地位將按照上市規則被取消。公司的股份自2022年7月2日起於聯交所暫停買賣。上市委員會認為公司未能於2023年1月1日前達成所有復牌指引,因此決定取消公司股份上市。
公司全體股東及投資者請留意,於2023年2月8日即股份在聯交所的最後上市日期後,即使股份的股票仍屬有效,股份將不會在聯交所上市及買賣,而公司亦毋須遵守上市規則。公司股份持有人如對有關取消上市地位的影響有任何疑問,請諮詢適當的專業意見。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.